{
    "id": "3b1267fd-ecfa-416f-969c-d601fa5b84a1",
    "indications": {
        "text": "lyrica cr indicated management : \u2022neuropathic pain associated diabetic peripheral neuropathy \u2022postherpetic neuralgia efficacy lyrica cr established management fibromyalgia adjunctive therapy adult patients partial onset seizures .",
        "doid_entities": [
            {
                "text": "peripheral neuropathy (DOID:574)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_574"
            },
            {
                "text": "neuropathy (DOID:870)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_870"
            },
            {
                "text": "fibromyalgia (DOID:631)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_631"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 lyrica cr administered daily evening meal . swallowed whole split , crushed , chewed . ( 2.1 ) \u2022 dosing recommendations lyrica cr : indication dosing regimen initial dose maximum dose dpn pain ( 2.2 ) single dose per day 165 mg/day 330 mg/day within 1 week . phn ( 2.3 ) single dose per day 165 mg/day 330 mg/day within 1 week . maximum dose 660 mg/day . \u2022 conversion lyrica capsules oral solution lyrica cr : full prescribing information . ( 2.4 ) \u2022 dose modification recommended patients renal impairment . ( 2.5 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "lyrica cr supplied following strengths package configurations : lyrica cr tablets package configuration tabletstrength ( mg ) ndc tablet description bottles 30 tablets 82.5 mg ndc 58151-245-93 light blue , film-coated , almond-shaped tablet debossed \u201c vle \u201d one side \u201c pgn 82.5 \u201d side bottles 30 tablets 165 mg ndc 58151-246-93 beige , film-coated , almond-shaped tablet debossed \u201c vle \u201d one side \u201c pgn 165 \u201d side bottles 30 tablets 330 mg ndc 58151-247-93 rose , film-coated , almond-shaped tablet debossed \u201c vle \u201d one side \u201c pgn 330 \u201d side store 20\u00b0c 25\u00b0c ( 68\u00b0f 77\u00b0f ) , excursions permitted 15\u00b0c 30\u00b0c ( 59\u00b0f 86\u00b0f ) original package . ( usp controlled room temperature )",
    "adverseReactions": "lyrica cr contraindicated patients known hypersensitivity pregabalin components . angioedema hypersensitivity occurred patients receiving pregabalin therapy [ ( 5.1 , 5.2 ) , ( 6 ) ] .",
    "ingredients": [
        {
            "name": "PREGABALIN",
            "code": "55JG375S6M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64356"
        },
        {
            "name": "CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE",
            "code": "0A5MM307FC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_60029"
        },
        {
            "name": "CROSPOVIDONE, UNSPECIFIED",
            "code": "2S7830E561"
        },
        {
            "name": "KOLLIDON SR",
            "code": "S34RY76LK6"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "organization": "Viatris Specialty LLC",
    "name": "Lyrica CR",
    "effectiveTime": "20250409",
    "indications_original": "LYRICA CR is indicated for the management of:\n                  \n                     \n                        \u2022Neuropathic pain associated with diabetic peripheral neuropathy\n                     \n                        \u2022Postherpetic neuralgia\n                  \n                  Efficacy of LYRICA CR has not been established for the management of fibromyalgia or as adjunctive therapy for adult patients with partial onset seizures.",
    "contraindications_original": "\u2022 LYRICA CR should be administered once daily after an evening meal. It should be swallowed whole and should not be split, crushed, or chewed. ( 2.1 ) \u2022 Dosing recommendations for LYRICA CR: Indication Dosing Regimen Initial Dose Maximum Dose DPN Pain ( 2.2 ) Single dose per day 165 mg/day 330 mg/day within 1 week. PHN ( 2.3 ) Single dose per day 165 mg/day 330 mg/day within 1 week. Maximum dose of 660 mg/day. \u2022 Conversion from LYRICA Capsules or Oral Solution to LYRICA CR: See full prescribing information. ( 2.4 ) \u2022 Dose modification recommended in patients with renal impairment. ( 2.5 )",
    "warningsAndPrecautions_original": "LYRICA CR is supplied in the following strengths and package configurations:\n                  \n                     \n                     \n                     \n                     \n                     \n                        \n                           \n                              \n                                 LYRICA CR Tablets\n                              \n                           \n                        \n                        \n                           \n                              \n                                 Package Configuration\n                              \n                           \n                           \n                              \n                                 TabletStrength (mg)\n                              \n                           \n                           \n                              \n                                 NDC\n                              \n                           \n                           \n                              \n                                 Tablet Description\n                              \n                           \n                        \n                        \n                           \n                              Bottles of 30 tablets\n                           \n                           \n                              82.5 mg\n                           \n                           \n                              NDC 58151-245-93\n                           \n                           \n                              Light blue, film-coated, almond-shaped tablet debossed with \u201cVLE\u201d on one side and \u201cPGN 82.5\u201d on the other side\n                           \n                        \n                        \n                           \n                              Bottles of 30 tablets\n                           \n                           \n                              165 mg\n                           \n                           \n                              NDC 58151-246-93\n                           \n                           \n                              Beige, film-coated, almond-shaped tablet debossed with \u201cVLE\u201d on one side and \u201cPGN 165\u201d on the other side\n                           \n                        \n                        \n                           \n                              Bottles of 30 tablets\n                           \n                           \n                              330 mg\n                           \n                           \n                              NDC 58151-247-93\n                           \n                           \n                              Rose, film-coated, almond-shaped tablet debossed with \u201cVLE\u201d on one side and \u201cPGN 330\u201d on the other side\n                           \n                        \n                     \n                  \n                  Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F), excursions permitted between 15\u00b0C and 30\u00b0C (between 59\u00b0F and 86\u00b0F) in the original package. (See USP Controlled Room Temperature)",
    "adverseReactions_original": "LYRICA CR is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see Warnings and Precautions (5.1, 5.2), Adverse Reactions (6)].",
    "drug": [
        {
            "name": "Lyrica CR",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_64356"
        }
    ]
}